| Everolimus 10 mg/day, N = 64 |
---|---|
PFS | Â |
   PFS events, n (%) | 35 (55) |
     Progression | 26 (41) |
     Death | 9 (14) |
   Censored observations, n (%) | 29 (45) |
Median PFS, months (95% CI) | 6.9 (3.7-12.5) |
Best Overall Response, n (%) | Â |
   Complete response | 0 |
   Partial response | 3 (5) |
   Stable disease | 39 (61) |
   Progressive disease | 8 (13) |
   Unknown* | 14 (22) |
Response analysis, n (%) | Â |
   ORR (CR or PR) | 3 (5) |
   [95% CI for ORR] | |
   DCR (CR or PR or SD) | 42 (66) |
   [95% CI for DCR] | [53–77] |
OS | Â |
   Median OS, months (95% CI) | NR (10.7-NR) |
   Probability of OS at 6 months,% (95% CI) | 76 (64–85) |
   Probability of OS at 12 months,% (95% CI) | 56 (42–68) |